Q3683260 (Q3683260): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item: importing one item from France) |
||||||||||||||
| Property / instance of | |||||||||||||||
| Property / instance of: Kohesio project / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / financed by | |||||||||||||||
| Property / financed by: European Union / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / country | |||||||||||||||
| Property / country: France / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
397,402.0 Euro
| |||||||||||||||
| Property / budget: 397,402.0 Euro / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
295,632.0 Euro
| |||||||||||||||
| Property / EU contribution: 295,632.0 Euro / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / co-financing rate | |||||||||||||||
74.39 percent
| |||||||||||||||
| Property / co-financing rate: 74.39 percent / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / start time | |||||||||||||||
1 January 2020
| |||||||||||||||
| Property / start time: 1 January 2020 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / end time | |||||||||||||||
31 December 2022
| |||||||||||||||
| Property / end time: 31 December 2022 / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / beneficiary name (string) | |||||||||||||||
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | |||||||||||||||
| Property / beneficiary name (string): INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary | |||||||||||||||
BIOLICAN vise à développer un dispositif technologique innovant non invasif capable de détecter des signatures moléculaires spécifiques dans le sang des patients atteints de cancer du poumon afin d’améliorer le diagnostic précoce et la prise en charge de la maladie. (French) | |||||||||||||||
| Property / summary: BIOLICAN vise à développer un dispositif technologique innovant non invasif capable de détecter des signatures moléculaires spécifiques dans le sang des patients atteints de cancer du poumon afin d’améliorer le diagnostic précoce et la prise en charge de la maladie. (French) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / intervention field | |||||||||||||||
| Property / intervention field: Research and innovation activities in public research centres and centres of competence including networking / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / fund | |||||||||||||||
| Property / fund: European Regional Development Fund / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / programme | |||||||||||||||
| Property / programme: Midi-Pyrénées et Garonne - ERDF/ESF/YEI / rank | |||||||||||||||
Normal rank | |||||||||||||||
Revision as of 15:29, 17 November 2021
Project Q3683260 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3683260 in France |
Statements
295,632.0 Euro
0 references
397,402.0 Euro
0 references
74.39 percent
0 references
1 January 2020
0 references
31 December 2022
0 references
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
0 references
BIOLICAN vise à développer un dispositif technologique innovant non invasif capable de détecter des signatures moléculaires spécifiques dans le sang des patients atteints de cancer du poumon afin d’améliorer le diagnostic précoce et la prise en charge de la maladie. (French)
0 references
Identifiers
MP0021775
0 references